$3.95
+0.15 (+3.95%)
Open$3.84
Previous Close$3.80
Day High$4.15
Day Low$3.81
52W High$13.13
52W Low$3.51
Volume—
Avg Volume43.9K
Market Cap31.66M
P/E Ratio—
EPS$-2.97
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+813.4% upside
Current
$3.95
$3.95
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.55M | 8.74M | 8.70M |
| Net Income | -23,908,138 | -76,794 | -87,592 |
| Profit Margin | -673.1% | -0.9% | -1.0% |
| EBITDA | -25,093,765 | -105,264 | -93,337 |
| Free Cash Flow | — | -51,137 | -57,721 |
| Rev Growth | — | +8.7% | -7.3% |
| Debt/Equity | — | 0.73 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |